Merck strengthens immunotherapy expertise with $773m buy
US-based Merck & Co has announced plans to buy Tilos Therapeutics, its latest acquisition in the immunotherapy space.
USITC issues judgment in cholesterol testing strips dispute
The US International Trade Commission has issued a judgment after a surgical appliances company, Polymer Technology Systems (PTS), filed a complaint against a China-based competitor.
Eli Lilly petitions SCOTUS in $20m Cialis suit
Eli Lilly has asked the US Supreme Court to reconsider a lower court’s ruling which ordered the drugmaker to pay Germany-based Erfindergemeinschaft UroPep $20 million for patent infringement.
US patent reforms could re-establish gene patent eligibility, industry experts warn
A group of more than 100 medical, scientific, patient advocacy and women’s health organisations have opposed a recent proposal to amend section 101 of the US Patent Act.
EU General Court rejects lactic acid supplement TM
The EU’s General Court has upheld the European Union Intellectual Property Office’s finding that a trademark for dietary supplements was descriptive of the relevant services to an Italian speaking public.
Eli Lilly licenses AI tech for preclinical development
San Francisco-based biotech company Atomwise could be set to receive up to $1 million per target in milestone payments following a partnership agreement with Eli Lilly.
German court deals blow to Sanofi over cholesterol drug
A German court has rejected a bid from French pharmaceutical company Sanofi to have a patent infringement case dismissed.
Danish biotech company secures CRISPR licence
Danish research company Bioneer has secured a non-exclusive licence to CRISPR/Cas9 technology owned by French geneticist Emmanuelle Charpentier.
Tokyo court dismisses Genentech patent suit against Sandoz
A Japanese court has dismissed a patent infringement lawsuit brought by Roche subsidiary Genentech against Sandoz, a division of Novartis.
FDA warns stem cell company over unapproved treatments
The US Food and Drug Administration has sent a warning letter to a stem cell company for marketing a number of unapproved treatments for a variety of life-threatening conditions.
